Tenvie Therapeutics

United States
South San Francisco, California, United States, 94080

Company profile

Tenvie Therapeutics company profile

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2025-01-01, Month

Headquarters

Postal code
94080
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$200M
Last funding
Series A / $200M / 2025-01-08
Last equity funding
Series A / $200M
Investors
3
Lead investors
3
Founders
2
Articles
17

Founders and investors

Founders

Brian CuneoTony Estrada

Lead investors

ARCH Venture PartnersF-PrimeMubadala Capital

Investors

ARCH Venture PartnersF-PrimeMubadala Capital